Company intelligence / Profile preview

FGMTM

Basel, Basel-Stadt, Switzerland

Ownership: Private
Employees: ~18000
Development stage: Other

Overview

Lonza is a leading global provider of integrated healthcare solutions, serving the pharmaceutical, biotech, and nutrition markets. The company operates as a major Contract Development and Manufacturing Organization (CDMO), offering services that span from early-stage research to commercial-scale production. Lonza's expertise includes the manufacturing of biologics, small molecules, cell and gene therapies, and capsules. The term "FGM™" specifically refers to their Fibroblast Growth Medium, a specialized product within their extensive portfolio of cell culture media and reagents used in life science research.

Modalities: Small moleculeMonoclonal antibodyCell therapyGene therapymRNA-based drugsPeptidesBiologic
Industry: Contract Manufacturing Organization

Partnerships

ModernaAstraZenecaBristol Myers SquibbSanofi

Beyond the preview

Go deeper on FGMTM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FGMTM.

Explore the full profile